Pierre Fabre's lung cancer pill wins FDA fast track with no data public
Pierre Fabre's elticertinib just landed FDA Fast Track for EGFR exon 20 insertion lung cancer that has already survived platinum chemo and amivantamab — but the company released no response rates or survival numbers. Rival zipalertinib, from Taiho and Cullinan, is already under FDA review with a Feb 27, 2027 action date.
- Original source: techtimes.com.
- The source published it on Nov 17, 2026 at 10:05 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Pierre Fabre announced at 4:30 a.m. ET Tuesday that the FDA handed elticertinib, an oral pill, a Fast Track designation for EGFR exon 20 insertion lung cancer that has progressed on both platinum chemotherapy and amivantamab. The company published no response rates, no survival figures, no safety numbers. Fast Track is not an approval: it unlocks more frequent FDA meetings, written feedback and the option to file finished sections of an application on a rolling basis. Where other therapies already exist, the FDA expects a drug to show some advantage over them, such as superior effectiveness or avoiding serious side effects.
Pierre Fabre says the designation rests on nonclinical data plus preliminary efficacy data from the ongoing Phase 1/2 trial NCT06043817. The company has not said how many patients have been treated, how many of them had prior amivantamab, what the recommended dose is, or when it plans a pivotal study or a filing. Fast Track drugs may also qualify for accelerated approval and priority review if relevant criteria are met — neither is guaranteed, and priority review is decided only when an application is filed.
The competition is already further down the road. Zipalertinib, from Taiho Oncology and Cullinan Therapeutics, had its application accepted in April for patients whose disease progressed on or after platinum chemotherapy, with or without prior amivantamab, and carries a Feb 27, 2027 action date. It rests on the Phase 2b REZILIENT1 trial, where 176 previously treated patients posted a confirmed response rate of about 35% and a median response duration of 8.8 months; in an exploratory look at 30 patients who had received amivantamab and no other exon 20 drug, the response rate was 30%. Taiho also filed a second application, announced Nov 12, for first-line use with chemotherapy, backed by Phase 3 REZILIENT3 data showing median progression-free survival of 14.5 months against 8.5 months on chemotherapy alone. No action date is set for that one.
Then there's sunvozertinib (Zegfrovy), the other oral rival, which won FDA accelerated approval on July 2, 2025 for patients who progressed on or after platinum chemotherapy. AstraZeneca agreed to license it from Dizal in a deal announced July 14, paying $600 million upfront with up to $900 million in milestones. In the first-line WU-KONG28 trial, median progression-free survival came in at 10.3 months versus 7.5 months on chemotherapy. Cross-trial comparisons between these single-arm and randomized studies are unreliable — and elticertinib has no public clinical numbers to compare at all.
The amivantamab angle is why the Fast Track wording matters. The FDA approved amivantamab (Rybrevant) with carboplatin and pemetrexed as first-line treatment for exon 20 insertion lung cancer on March 1, 2024, based on the 308-patient PAPILLON trial, making that combination the standard of care and pushing more patients into later treatment already exposed to it. An OncLive account of a presentation by Dr. Zosia Piotrowska of Massachusetts General Hospital put zipalertinib's response rate at 30% after amivantamab alone, but 14% in the 21 patients who had also taken another exon 20 inhibitor. That analysis did not cover elticertinib, and whether it works after another exon 20 pill is not publicly known.
Elticertinib started life as STX-721, which Scorpion Therapeutics described as targeting EGFR exon 20 insertion mutants when it announced its Pierre Fabre partnership. Scorpion licensed the program in April 2023 for $65 million upfront plus near-term payments and up to $553 million in potential milestones, keeping U.S., Canadian and Japanese rights; the first patient was dosed in the Phase 1/2 trial in October 2023. On June 16, 2025, Pierre Fabre said it had acquired worldwide rights to PFL-721 and PFL-241 from Antares Therapeutics, a Scorpion spin-out, and taken over clinical development. The cautionary precedent is mobocertinib, which carried a heart-rhythm warning and diarrhea as a common side effect before being withdrawn from the market — and whether elticertinib avoids those problems can't be judged, because no clinical safety data are public.
TopicsPierre Fabre · elticertinib · FDA · zipalertinib · Taiho Oncology · Cullinan Therapeutics · AstraZeneca · sunvozertinib
Source: techtimes.com
Written by AI from verified reporting.
More stories
- Health & science yahoo.com 0 viewsFDA clears GSK lung cancer drug for advanced cases
- Health & science curetoday.com 0 viewsFDA Fast-Tracks Nelkarmi for Lung Cancers That Outsmarted Earlier Drugs
- Health & science apnews.com 0 viewsUS and Mexico stripped of measles-free status, international health officials say
- Health & science cbsnews.com 0 viewsChina fires scientist after girl, 6, died in hidden gene-editing trial

